<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01393197</url>
  </required_header>
  <id_info>
    <org_study_id>TMU-CIH-IR-003</org_study_id>
    <nct_id>NCT01393197</nct_id>
  </id_info>
  <brief_title>Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)</brief_title>
  <acronym>TACE-KMG</acronym>
  <official_title>Clinical Trial of Transcatheter Arterial Chemoembolization (TACE)With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Transcatheter Arterial
      Chemoembolization (TACE) with KMG microsphere in treating HCC. And to determine which one is
      better,KMG microsphere or lipiodol?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most important part of effect in TACE is embolization .But there is no clinical trials on
      which one is better,KMG microsphere or lipiodol? what effect did chemo play in the TACE
      treating HCC? Which one is better,routine dose or low dose? Experts in USA and Japan had
      their own researches and standpoints.We think it is important to push a clinical trail to
      answer these problem.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>3 years</time_frame>
    <description>Time to progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total survival</measure>
    <time_frame>3 years</time_frame>
    <description>total survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission rate</measure>
    <time_frame>3 years</time_frame>
    <description>remission rate</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">2480</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>TACE -oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE-KMG ( routine dose Chemo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE-KMG( low dose Chemo )</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE-KMG(without chemo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>embolization agent:KMG microsphere( 150-450µm,0.2-2g)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic Chemoembolization</intervention_name>
    <description>Transcatheter Arterial Chemoembolization</description>
    <arm_group_label>TACE -oil</arm_group_label>
    <arm_group_label>TACE-KMG ( routine dose Chemo)</arm_group_label>
    <arm_group_label>TACE-KMG( low dose Chemo )</arm_group_label>
    <arm_group_label>TACE-KMG(without chemo)</arm_group_label>
    <other_name>Transcatheter Arterial Chemoembolization，TACE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatocellular Carinomas with diagnosis of pathology or cytology or consistent with
             China 2001 guideline of Clinical Diagnosis Hepatocellular Carinomas clinical stage（The
             Barcelona Liver Clinic staging system,BCLC B and C)，or can not receive surgical
             intervention

          -  liver function:Child-Pugh A、B

          -  PST 0—1（Eastern Cooperative Oncology Group Performance Score ,ECOG）

          -  Lifespan≥6 months

          -  First time to receive treatment

          -  Can accept the follow up

          -  informed consent was gotten

          -  the number of lesion ≤ 5

        Exclusion Criteria:

          -  pregnant or lactation woman

          -  emotional disturbance

          -  serious heart ,lung disfunction or serious diabetes mellitus

          -  serious reactiveness infections;（exp:type B or C hepatitis）

          -  liver function :Child-Pugh Score C

          -  thrombocyte＜6×109/L

          -  diffuse HCC

          -  widespread metastasis

          -  serious atherosclerosis

          -  acquired immunodeficiency syndrome;AIDS

          -  thrombosis or thrombosis event in 6 months

          -  renal inadequacy who need hemodialysis or peritoneal dialysis

          -  with other tumors except basal cell carcinoma and carcinoma in situ of cervix

          -  serious alimentary tract hemorrhage in 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi Guo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhi Guo, MD</last_name>
    <phone>13920076145</phone>
    <email>cjr.guozhi@vip.163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haipeng Yu, MD</last_name>
    <phone>13352070835</phone>
    <email>jieruke@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Guo, MD</last_name>
      <phone>13920076145</phone>
      <email>cjr.guozhi@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Haipeng Yu, MD</last_name>
      <phone>13352070835</phone>
      <email>jieruke@yahoo.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.tjmuch.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2011</study_first_submitted>
  <study_first_submitted_qc>July 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2011</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

